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Abstract
STAT3 is a transcription factor that has been found to be constitutively activated in a number of human cancers.
Dimerization of STAT3 via its SH2 domain and the subsequent translocation of the dimer to the nucleus leads to
transcription of anti-apoptotic genes. Prevention of the dimerization is thus an attractive strategy for inhibiting the activity
of STAT3. Phosphotyrosine-based peptidomimetic inhibitors, which mimic pTyr-Xaa-Yaa-Gln motif and have strong to weak
binding affinities, have been previously investigated. It is well-known that structures of protein-inhibitor complexes are
important for understanding the binding interactions and designing stronger inhibitors. Experimental structures of
inhibitors bound to the SH2 domain of STAT3 are, however, unavailable. In this paper we describe a computational study
that combined molecular docking and molecular dynamics to model structures of 12 peptidomimetic inhibitors bound to
the SH2 domain of STAT3. A detailed analysis of the modeled structures was performed to evaluate the characteristics of the
binding interactions. We also estimated the binding affinities of the inhibitors by combining MMPB/GBSA-based energies
and entropic cost of binding. The estimated affinities correlate strongly with the experimentally obtained affinities.
Modeling results show binding modes that are consistent with limited previous modeling studies on binding interactions
involving the SH2 domain and phosphotyrosine(pTyr)-based inhibitors. We also discovered a stable novel binding mode
that involves deformation of two loops of the SH2 domain that subsequently bury the C-terminal end of one of the stronger
inhibitors. The novel binding mode could prove useful for developing more potent inhibitors aimed at preventing
dimerization of cancer target protein STAT3.
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Introduction
Development of effective therapeutics is the ultimate goal of
cancer research [1–6], but it is a time-consuming and expensive
process [7–10]. Structure-based computational techniques [11,12]
such as virtual screening [13–15], docking [16,17], and molecular
dynamics [18,19] have proven useful in the development of drugs.
Even if there have not been many successful drug discovery stories
based on computation alone, the use of structure-based compu-
tational techniques has helped gain better understanding of how a
putative drug compound binds to its target receptor, and has
reduced the drug development time and costs [20–22]. In this
paper, we discuss computational modeling of binding interactions
between a specific set of peptidomimetic inhibitors [23–26] and
the Src-homology 2 (SH2) domain of STAT3 or Signal
Transducer and Activator of Transcription 3 [27] (Figure 1).
STAT3 is constitutively activated in a number of human cancer
types such as lung cancer, breast cancer, multiple myeloma, and
others [28–30]. The Jak-STAT pathway [31,32] describes the
mechanism of action that leads to the transcription of anti-
apoptotic genes. Upon extracellular signaling, a series of
phosphorylations of cell surface receptors and Janus kinases
(JAKs) inside the cell results in the phosphorylation of STAT3. A
phosphorylated STAT3 then forms a dimer via its SH2 domain
and the dimer translocates to the nucleus where it is involved in
the transcription process.
Our focus in this work is on 12 peptidomimetic [23–26](mimic
pTyr-Xaa-Yaa-Gln motif) inhibitors that target the SH2 domain
of STAT3 with the aim of preventing the dimerization of STAT3,
and subsequent translocation and transcription. The experimental
structures of the peptidomimetics bound to the SH2 domain are
unavailable. However, the experimental binding affinities, which
measure the thermodynamic stability of binding interactions
between the peptidomimetics and the SH2 domain, have been
derived using fluorescence polarization [33]. Our goal is to
computationally model the binding modes which define how a
conformation of a peptidomimetic binds to the conformation of
the SH2 domain, analyze the binding interactions, estimate the
binding affinities, and calculate the correlation between the
estimated and the experimental binding affinities.
Our computational modeling approach combines molecular
docking and molecular dynamics and derives inspiration from
previous work [18,24,34–39]. Given a protein and an unbound
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ligand, molecular docking computes the preferred conformation
and location of the ligand in the binding pocket of the protein.
Many molecular docking programs exist (see representative
examples [40–48]) and several docking studies have been
performed with varied amount of success (e.g., [49–57]). Three
major limitations however remain.
N A docking program typically computes the best conformation
and placement of the ligand such that it minimizes an energy
function specific to the docking program. The energy function
approximates the free energy of binding and, in general,
accuracy of the binding energy is sacrificed so that the
computation of energy can be performed in minimal time. The
approximate energy functions, therefore, may result in
conformations that are not accurate [58–60].
N Most docking programs treat the protein as a rigid molecule
or, at the very best, a molecule with limited flexibility. Thus,
most of these programs perform what is known as flexible
ligand docking to a rigid receptor. However, it is well known
that more accurate modeling of binding interactions between a
ligand and a receptor requires accounting for the flexibility of
the receptor [61,62].
N Docking of small ligands with 5 or 6 rotatable bonds is fairly
accurate and computationally fast. However, docking of large
ligands with many rotatable bonds, such as the peptidomimetic
inhibitors in our dataset, is inaccurate and computationally
expensive. A large number of rotatable bonds increases the
dimensionality of the conformation space of the ligand which
makes searching for the docked conformation extremely
challenging and time-consuming [57,63,64].
Our modeling approach addresses the above limitations in the
following way. Docking of a peptidomimetic is first done with an
AutoDock [44,65]-based incremental docking protocol that we
have developed recently [66]. A molecular dynamics simulation of
the docked conformation of the peptidomimetic in complex with
the SH2 domain is then performed. Using molecular dynamics, we
are able to treat both the ligand and the receptor as flexible and,
more importantly, we analyze deformations in the structure of the
complex in a simulated solvent environment. The physics-based
force field used in the molecular dynamics simulations is more
detailed and accurate as compared to the energy functions used in
molecular docking. Molecular dynamics simulation thus also lends
itself to calculation of more accurate binding affinity estimates
[67,68].
Using our modeling approach, we show that we were able to
obtain various binding modes for the peptidomimetics. Not only
did we obtain previously proposed binding modes [24,69], but we
also obtained a novel binding mode. The estimated binding
affinities and the experimental binding affinities are well correlated
which validates our modeling approach. By using the estimated
binding affinities and conformational analysis of the molecular
dynamics trajectories, we are able to differentiate between strong
and weak binders. In the following section, we present details of
our peptidomimetic dataset, explain our computational modeling
approach, binding affinity calculations, and data analysis tech-
niques. This is followed by a description of the results from the
computational modeling of the peptidomimetics in complex with




The 12 inhibitors used in this study were obtained from a series
of 142 peptidomimetic compounds [23–26]. These 142 peptido-
mimetics mimic pTyr-Xaa-Yaa-Gln motif and were developed to
bind to the SH2 domain with the purpose of inhibiting the activity
of STAT3. The binding affinities (measured as IC50 values) of the
142 peptidomimetics were evaluated using fluorescence polariza-
tion [33]. The IC50 value gives the concentration of the
peptidomimetic that is required to competitively inhibit the
binding of FAM-Ala-pTyr-Leu-Pro-Gln-Thr-Val-NH2 (FAM = 5-
carboxyfluorescein) to Stat3 by 50% [23]. The binding affinities of
the 142 peptidomimetics were found to range from weak
(IC50 = 100,000 nM) to strong (IC50 = 39 nM).
The molecular dynamics simulation, which is part of our
modeling approach, and the method used for the estimation of
binding affinities (see sections below) are computationally expen-
sive. Therefore, we limited our modeling study to 12 peptidomi-
metics. The 12 peptidomimetics used in this study were chosen
such that they represent a range of values of the experimental
binding affinities as shown in Figure 2 and also represent a range
of sizes varying from 9 torsional degrees of freedom to 22 torsional
Figure 1. STAT3 structure. Protein Data Bank (ID 1BG1) structure of STAT3 is shown. The structure has four domains: a N-terminal four-helix
bundle (in blue, residues 138–320), an eight-stranded b-barrel (in purple, residues 321–465), an a-helical connector domain (in green, residues 466–
585), and a SH2 domain (in yellow, residues 586 to 688).
doi:10.1371/journal.pone.0051603.g001
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degrees of freedom. Each peptidomimetic was named such that
the compound number represents the order in which the
peptidomimetic appears in the original publications [23–26]
where the 142 peptidomimetics were first described.
The structure of STAT3 was obtained from the Protein Data
Bank [70] (PDB ID 1BG1). The structure contains residues 136 to
716 of Stat3, half a DNA duplex, and 127 water molecules per
asymmetric unit [27]. Since we are interested in the modeling of
the peptidomimetics bound to the SH2 domain, the structure of
the SH2 domain corresponding to residues 585 to 688 (Figure 1)
was isolated. The water molecules and the DNA duplex were
ignored. Using the molecular builder of the Maestro software [71]
(version 9.1), the 2-D chemical representations of the 12
peptidomimetics (Figure 2) were converted to 3-D structures of
the unbound peptidomimetics.
Modeling Approach
Our two-step computational modeling approach combined
molecular docking and molecular dynamics. Molecular docking of
a large ligand such as a peptidomimetic with many rotatable bonds
is challenging. A large ligand spans a high-dimensional confor-
mation space which makes exploration of docked conformation of
the ligand challenging. Our recently developed Autodock-based
incremental docking protocol has been shown to improve docking
of large ligands [66]. Therefore, we first docked the 12
peptidomimetic inhibitors in our dataset to the SH2 domain of
STAT3 using our incremental docking protocol [66], and
subsequently performed molecular dynamics simulations of the
docked conformations of the peptidomimetics in complex with the
SH2 domain.
Starting from a fragment of the ligand, at each incremental step,
our docking protocol explores a few rotatable bonds, then selects a
small number of best partially docked fragments, grows the
fragments by adding few more rotatable bonds and atoms, and
docks again. The dock-select-grow-dock process is repeated until
all the rotatable bonds in the ligand are explored. AutoDock
[44,65] is used in each step to explore only a few rotatable bonds
and this makes the docking operation fast and accurate.
Each peptidomimetic in our dataset was docked to the SH2
domain of STAT3 using our incremental docking protocol. Since
Figure 2. 12 peptidomimetics. 2-D chemical representations of the 12 peptidomimetics that form our dataset are shown. IC50 value represents
the experimental binding affinity of each peptidomimetic derived using fluorescence polarization and N represents the number of rotatable bonds in
each peptidomimetic.
doi:10.1371/journal.pone.0051603.g002
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the phosphate group of the pTyr residue in each peptidomimetic is
known to bind to the sub-pocket formed by residues Lys591,
Arg609, Ser611, Glu612, and Ser613 [24,69], at each incremental
docking step we selected conformations with the lowest values of
scoring function S, where
S~0:25(Pd )zSAD, ð1Þ
Pd is the squared distance of the phosphorus atom (in pTyr) from
coordinates ({8:42,4:50,{6:09) that represent approximate
center of the sub-pocket, and SAD is the binding affinity estimated
by AutoDock’s energy function. The scoring function S, thus,
penalizes large distance between the phosphate group and the sub-
pocket. The details of the incremental docking of peptidomimetics
and scoring function S are available in the Supporting Information
(Section S1).
After all the rotatable bonds in a peptidomimetic were explored
and all its atoms were docked, the docked conformation of the
peptidomimetic with the lowest value of S (see, equation (1)) was
selected. For each peptidomimetic in our dataset, molecular
dynamics simulation of the selected docked conformation, in
complex with the SH2 domain of STAT3, was performed. The
sander module in the AMBER11 software package [72] was used
for the simulation. The peptidomimetic inhibitor was described
with generalized amber force field [73] (GAFF), and point charges
were calculated for the atoms using antechamber module (from
AmberTools software package [74] version 1.5) and AM1-BCC
charge model. The protein was described with AMBER’s ff99SB
force field. The complex was solvated in a 15 A˚ octahedral box of
TIP3P water and the whole system was neutralized by adding Na+
counterions according to the net charge of the peptidomimetic.
Table S1 lists the number of atoms in each of the 12 molecular
dynamics systems.
The complex was first minimized using 100 cycles of steepest
descent minimization followed by 1900 cycles of conjugate
gradient minimization. This was followed by 50 ps of temperature
equilibration where the temperature was raised from 100 K to
300 K using Berendsen [75] control with coupling parameter set
to 2 ps. Pressure equilibration was then performed for 200 ps
using Berendsen control with pressure relaxation time set to 2 ps.
Finally, a production simulation of 10 ns was performed at
constant temperature and pressure, and the trajectory was output
at every 10 ps. During the molecular dynamics simulation,
SHAKE algorithm was used to constrain bonds involving
Figure 3. Docked conformations. Docked conformation of each peptidomimetic that was obtained using our incremental docking protocol is
shown. The peptidomimetic conformation (in green) is shown in complex with the SH2 domain of STAT3 (in surface representation). The surface
coloring shows the Coulombic electrostatic potential in different regions of the surface of the SH2 domain. The potential ranges from positive (in
blue) to negative (in red). IC50 value represents the experimental binding affinity of each peptidomimetic derived using fluorescence polarization and
N represents the number of rotatable bonds in each peptidomimetic.
doi:10.1371/journal.pone.0051603.g003
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hydrogen atoms and therefore forces for the bonds involving
hydrogen atoms were not calculated. For computing electrostatic
energies, Particle Mesh Ewald [76] (PME) method was used with
the non-bonded cutoff set to the default value of 8 A˚. Plots
showing variation of system properties (total energy, potential
energy, temperature, and pressure) during the production
simulation are available in the Supporting Information (Figures
S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, and S12) and reveal
equilibrated and stable systems.
To evaluate the accuracy of our modeling approach, we
performed a study where we compared the structures modeled
using our approach with experimentally-derived structures. Since
experimentally determined structures of the peptidomimetics in
complex with the SH2 domain of STAT3 or any other protein
from the STAT family are unavailable, the validation was done
using a dataset of similar complexes derived from the PDBbind
database [77]. The details and analysis of the validation study are
available in the Supporting Information (Section S2). The analysis
(Figures S13, S14, S15, S16, S17, S18, S19, S20, S21, and S22,
Table S2) shows that the modeled structures and experimental
structures are spatially close and therefore we conclude that our
modeling approach is well-suited for modeling of peptidomimetic-
SH2 complexes that are described in this paper.
Binding Affinities
Trajectories obtained from molecular dynamics simulations
were also used to estimate binding affinities. The binding affinity
of each peptidomimetic in complex with the SH2 domain was
obtained using Molecular Mechanics Poisson Boltzmann (or
Generalized Born) Surface Area (MMPB/GBSA) calculations
[78]. The binding affinity is given by
DGbind~DEMMzDGPB=GBzDGSA{TDS ð2Þ
where, T is the temperature, DEMM represents the molecular
mechanics energy, DGPB=GB represents the polar part of solvation
energy, DGSA represents the non-polar part of the solvation
energy, and TDS represents the energetic penalty due to loss of
entropy upon binding.
To compute DGbind , values of DEMM , DGPB=GB, and DGSA
were computed averaged over the snapshots of the molecular
dynamics production trajectory. The TDS value was computed
from a normal mode analysis of the system using nmode module of
the AmberTools [74] package. For entropy computation, every
10th snapshot of the molecular dynamics trajectory was used.
Calculations of all of the above DGbind components were done
using MMPBSA script provided by the AmberTools package. For
computing the polar part of solvation energy using Poisson-
Boltzmann calculations, the ionic strength was set to 0.1 mM. All
other parameters needed by MMPBSA script were kept at their
default values.
Data Analysis
Trajectory data obtained after the 10 ns molecular dynamics
simulation was analyzed in a variety of ways. Prior to analyzing the
data, however, the following processing was done. Water and
counterions were removed from the trajectory data. All atoms
were moved such that the center of mass of the complex moved to
the center of the simulation box and imaging was done to bring all
atoms inside the primary unit cell. All conformations of the
complex contained in the snapshots of the trajectory were then
fitted to the conformation in the first frame of the production
simulation. Mass-weighted root mean squared distance (RMSD)
fitting was done. Note that since we output trajectory at every
10 ps, we obtained 1000 snapshots or conformations of the
complex from a 10 ns molecular dynamics simulation.
Average (mass-weighted) root mean square fluctuations (RMSF)
were computed for each peptidomimetic bound to the SH2
Figure 4. Root mean square fluctuations. Root mean square fluctuation (RMSF) of the 12 peptidomimetics in complex with the SH2 domain of
STAT3 is shown. Each RMSF value was computed using 1000 conformations of the peptidomimetic derived from the 10 ns molecular dynamics
trajectory.
doi:10.1371/journal.pone.0051603.g004
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domain. The RMSF value represents the average value of the
RMSD between the peptidomimetic conformation in the first
frame of the molecular dynamics trajectory and the conformations
in the subsequent frames. Thus, the RMSF value is indicative of
the time-averaged fluctuation of the peptidomimetic conforma-
tion. Clustering of conformations of the peptidomimetic was done
and conformations that are representative of the clusters were
identified. Clustering was done using k-means [79] (k was set to 5)
algorithm with RMSD as the similarity metric. Hydrogen bonds
are critical for stabilizing the binding interactions [80–83] and
were identified between each peptidomimetic and the SH2
domain. If a hydrogen bond was present in less than 50% of the
conformations in the trajectory, it was ignored. For each
peptidomimetic in complex with the SH2 domain, we computed
the hydrogen bond occupancy of the residues of the SH2 domain.
Hydrogen bond occupancy of a residue is defined as the fraction of
conformations in the molecular dynamics trajectory that contain at
least one hydrogen bond involving that particular residue.
Computation of RMSF values and k-means clustering was done
using ptraj module from the AmberTools [74] package. Hydrogen
bonds were identified using hbond tool in the Chimera software
package [84] version 1.6.
Results
Conformational Analysis
Figure 3 shows the best docked conformation, of each of the 12
peptidomimetics, computed using the incremental docking proto-
col. These docked conformations were then solvated and subjected
to 10 ns of molecular dynamics simulations. Snapshots of the
trajectories were output at every 10 ps and therefore we obtained
1000 conformations for each of the 12 pepetidomimetic-SH2
domain complexes. The RMSF value for each peptidomimetic is
shown in Figure 4. The RMSF value quantifies the average spatial
fluctuation of the peptidomimetic conformation in the 1000
snapshots. A low RMSF value is thus indicative of spatial stability
of the conformation of the peptidomimetic bound to the SH2
domain. The RMSF values for weak binders such as comp13,
comp15, and comp60 are higher as compared to the RMSF values
Figure 5. Representative conformations after clustering. For each peptidomimetic, 5 conformations in complex with the SH2 domain (in gray)
of STAT3 are shown. The 5 conformations are the representatives of the 5 clusters obtained after k-means clustering of the 1000 conformations that
were derived from 10 ns molecular dynamics trajectory of each peptidomimetic-SH2 domain complex. IC50 value represents the experimental
binding affinity of each peptidomimetic derived using fluorescence polarization and N represents the number of rotatable bonds in each
peptidomimetic.
doi:10.1371/journal.pone.0051603.g005
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Figure 6. Residues involved in hydrogen bonds. The residues (labeled) of the SH2 domain that form hydrogen bonds with at least one of the
12 peptidomimetics are shown. The top figure shows a cartoon representation of the SH2 domain and the bottom figure shows a surface
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of the strong binders such as comp70, comp121, comp134,
comp135, and comp136. As an exception, comp140, another
strong binder, shows surprisingly large RMSF value (1.82 A˚) that
is comparable to the RMSF values of the weak affinity
peptidomimetics.
Through clustering of the 1000 conformations, we obtained 5
representative conformations of each peptidomimetic-SH2 com-
plex (Figure 5). All representative conformations have the
phosphate group of the pTyr residue or its surrogate in the
location of the corresponding pTyr705 in the crystal structure of
STAT3 [27]. The representative conformations of the strong
binders such as comp70, comp121, comp134, comp135, and
comp136 are spatially similar, while those of weak binders such as
comp13, comp15, and comp60 show more spatial variation.
Hydrogen Bonds
Hydrogen bonds are critical to the binding interactions between
the peptidomimetics and STAT3. Figure 6 shows all the residues
that are involved in hydrogen bonds with at least one
peptidomimetic. Residues Lys591, Arg609, Ser611, Glu612, and
Ser613 are involved in the hydrogen bond interactions and form
the phosphate-binding pocket (sub-pocket-1) where the phosphate
group of pTyr residue (or its surrogate) in each peptidomimetic
binds. Three sub-pockets in the binding site of the SH2 domain
are also involved in hydrogen-bonding interactions. Residues
Glu638, Tyr640, and Gln644 form sub-pocket-2, residues Gly656,
Lys658, and Tyr657 form sub-pocket-3, and residues Trp623,
Ile659, and Met660 flank sub-pocket-4.
The residues of the SH2 domain which participate in hydrogen
bonds with a specific peptidomimetic and the hydrogen bond
occupancy involving those residues and the peptidomimetic are
shown in Figure 7. The occupancy plots in Figure 7 also show that
the strong binders such as comp70, comp121, comp134, and
comp136 form hydrogen bonds with more than 5 residues of the
SH2 domain, and the weak binders such as comp13 and comp15
form hydrogen bonds with 3 and 4 residues respectively. Another
weak-affinity peptidomimetic comp60 forms hydrogen bonds with
6 different residues but all of these residues surround the
phosphate-binding pocket (sub-pocket-1). This means that, in the
case of comp60, while the pTyr residue binds tightly to the sub-
pocket-1, the rest of the peptidomimetic is not involved in stable
hydrogen bond interactions. A couple of strong binders, comp135
and comp140, form hydrogen bonds with 4 residues each. Since
the conformation of comp140 is unstable (as evident by the RMSF
value) and we ignore hydrogen bonds if they are present in less
than 50% of the conformations in the molecular dynamics
trajectory, hydrogen bond interactions with fewer residues of the
SH2 domain is expected. In the case of comp135, however, the
RMSF value is low (1.22 A˚). We postulate that comp135 may have
an alternate and more stable bound conformation similar to the
conformation of comp134.
Binding Affinity
The binding affinity value reflects the thermodynamic stability
of the binding interactions between a peptidomimetic and the SH2
domain of STAT3. In a computational modeling study such as
this, a large positive correlation between the experimental binding
affinities and estimated binding affinities is desired. A high
correlation allows accurate prediction of strong and weak binders.
We used binding energy function described by equation (2) to
estimate the binding affinity values in four different schemes: A.
entropic component (TDS) was ignored and the non-entropic
component was computed using MMGBSA, B. entropic compo-
nent (TDS) was ignored and the non-entropic component was
computed using MMPBSA, C. entropic component (TDS) was
included and the non-entropic component was computed using
MMGBSA, and D. entropic component (TDS) was included and
the non-entropic component was computed using MMPBSA. The
experimental binding affinities were calculated from the IC50
values using the function
DGexp~R|T|logKi ð3Þ




mol, R (Gas constant) = 0.001986 k-
cal K-1 mol-1, T = 298 K, and IC50 values are in nM. The Cheng-
Prusoff estimation [85] of Ki from IC50 was done using a Kd of
150 nM for FAM-Ala-pTyr-Leu-Pro-Gln-Thr-Val-NH2[86] and a
concentration of 10 nM in the fluorescence polarization assay used
to evaluate the binding affinities of the 12 peptidomimetics [23].
Figure 8 (top) plots Pearson’s correlation coefficient (R), that
measures the correlation between the experimental and estimated
binding affinities, versus the length (2 ns, 4 ns, 6 ns, 8 ns, and
10 ns) of molecular dynamics simulation. Note that the binding
affinities are computed averaged over the snapshots of the
molecular dynamics simulation. From the figure, it is clear that,
for all four affinity estimation schemes, the value of R increases
with the increase in the length of molecular dynamics simulation.
Out of the four schemes, the best correlation coefficient values
were observed for the scheme D (cyan) which estimates affinity as a
sum of the entropic component and the MMPBSA-based non-
entropic component of the energy function. The maximum
observed value of R is 0.63 which was computed using scheme
D and 10 ns molecular dynamics simulation trajectories.
The estimated binding affinities, for the 12 peptidomimetics,
obtained using scheme D are shown in Figure 8 (bottom). For each
peptidomimetic, multiple values of the binding affinities that
correspond to different lengths of molecular dynamics simulation
are shown. It is clear that the affinity values converge as the length
of simulation increases. The affinity values, derived from the 10 ns
molecular dynamics trajectories, correspond to the R value of 0.63
as described above. Since the R value is large, not surprisingly,
weak binders such as comp13, comp15, and comp60 have higher
estimated affinity values, the value for comp15 (IC50.
100,000 nM) being the highest (218.22 kcal/mol). Similarly, the
binding affinity values for strong binders such as comp70,
comp121, comp134, and comp136 are low, the value for comp70
(IC50 = 190 nM) being the lowest (245.40 kcal/mol).
Binding Modes
The conformations in Figure 5 show the presence of two
binding modes that have also been described in previous
computational modeling studies [24,69]: the bent mode and the
extended mode. All or some of the representative conformations
for comp70, comp135, comp140, and comp142 display the bent
mode where the phosphate group sits in sub-pocket 1 and the
peptidomimetic bends such that the Gln (or its derivative) residue
of the peptidomimetic sits in sub-pocket 2. In the extended mode,
representation. The surface coloring shows the Coulombic electrostatic potential in different regions of the surface of the SH2 domain. The potential
ranges from positive (in blue) to negative (in red). Note that a hydrogen bond is ignored if it is present in less than 50% of the conformations in the
10 ns molecular dynamics trajectory.
doi:10.1371/journal.pone.0051603.g006
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as seen in all or some of the representative conformations for
comp134, comp136, comp140, and comp142, the phosphate
group sits in sub-pocket 1 and the backbone extends such that Gln
(or its derivative) residue of the peptidomimetic sits in sub-pocket
3. Apart from the bent and the extended modes, a novel binding
mode was observed. The five representative conformations of
comp121 display what we term a wedged mode. In this mode,
while the phosphate group binds to the sub-pocket-1, the other
end of the peptidomimetic is wedged in a groove formed by two
loops of the SH2 domain described by residues 623–629 and
residues 656–668.
The binding modes are shown in detail in Figures 9, 10, and
11. Both cartoon and surface representations of the SH2
domain are shown. The labeled yellow residues of the SH2
domain are involved in hydrogen bond interactions and the
hydrogen bonds are shown with dashed black lines. The surface
of the SH2 domain is colored using the Coulombic surface
coloring scheme in the Chimera software package. The surface
is characterized by electrostatic potentials ranging from positive
electrostatic potential (blue surface) to a negative potential (red
surface). The bent mode is displayed by the peptidomimetic
comp70 (Figure 9), the extended mode is displayed by comp134
(Figure 10), and the wedged mode is displayed by comp121
(Figure 11). The binding affinities of the three peptidomimetics,
experimental as well as computed, are high (low DG and IC50
values) and, as shown in Figure 4, the RMSF values for
comp70 (0.98 A˚), comp134 (0.95 A˚), and comp121 (0.91 A˚) are
the lowest out of the RMSF values for the 12 peptidomimetics.
Thus, these three compounds present a strong evidence that
there are three possible modes in which peptidomimetics can
tightly bind to the SH2 domain.
As expected, all three binding modes include multiple
hydrogen bonds connecting the phosphate group to sub-
pocket-1. The amino acids forming sub-pocket-1 create a strong
positive electrostatic potential which thus tightly binds the
negatively charged phosphate group in all peptidomimetics. In
the bent mode (Figure 9), the Gln residue of comp70 binds to
the sub-pocket-2 and forms multiple hydrogen bonds with
residues Tyr640 and Gln644 of the SH2 domain that flank sub-
pocket-2. The binding interactions are also stabilized by the
hydrogen bonds formed between the carbonyl oxygen of the
Haic group and residue Tyr657 of the SH2 domain. A similar
interaction was observed between a carbonyl oxygen of pTyr-
Asp-Lys-Pro-His and Tyr651 in the crystal structure of STAT1
[87]. In the extended mode (Figure 10), the carbonyl oxygen of
the Leu at pTyr+1 position forms hydrogen bond with Tyr657
and the side chain amide group of the Gln-mimic residue at the
C-terminus of the peptidomimetic forms hydrogen bonds with
the main chain C = O of Gly656 and the backbone NH groups
of Lys658 and Ile659. In the newly discovered wedged mode
(Figure 11), the carbonyl oxygen of the Leu residue forms
hydrogen bond with Trp623 which lies on the loop formed by
residues 623–629 and the carbonyl oxygen of methanoproline is
involved in a hydrogen bond with the side chain OH of
Tyr657. The driving force for this binding mode appears to be
hydrophobic contact between the C-terminal benzene ring and
residues of loops 623–629 and 656–658 as well as a hydrogen
bond between the benzylamide NH and the main chain C = O
of Met660. Interestingly, the side chain amide group of Gln
does not appear to interact directly with the protein.
Discussion
Transcription factor STAT3 is an important target protein that
is involved in a multitude of human cancers. In this work, we
focused on a specific set of 12 peptidomimetic compounds that
mimic the pTyr-Xaa-Yaa-Gln recognition motif and were
designed to bind with the SH2 domain of STAT3 and prevent
its dimerization which is a critical event leading up to the
transcription of anti-apoptotic genes. Experimental binding
affinities of the peptidomimetics were measured using fluorescence
polarization and a range of affinity values were observed for the 12
peptidomimetics. Binding affinities for the peptidomimetics,
expressed as IC50 values, range from 39 nM for a strong binder
to over 100,000 nM for a weak binder. Since experimental
structures of the complexes formed between the peptidomimetics
and the SH2 domain are unavailable, we used a computational
strategy to model the complexes.
Our modeling strategy proceeded in two steps. In the first, we
generated docked conformations of the peptidomimetics using a
computational AutoDock-based incremental docking protocol that
was developed by us for docking large compounds in a fast and
accurate manner [66]. The peptidomimetics in our dataset are all
large compounds with the number of rotatable bonds ranging
from 9 to 22. In the second step of our modeling strategy, we
selected the best docked conformation and then ran molecular
dynamics simulations of the complex in a solvated box. Molecular
dynamics simulations served multiple purposes. The flexibility of
the SH2 domain was taken into account, fluctuations of the bound
conformations over the length of molecular dynamics simulation
were computed, and finally, rigorous estimates of binding
affinities, as a sum of normal-mode analysis based entropic
component and MMPB/GBSA based non-entropic component,
were computed. Accurate estimates of binding affinities are very
important for differentiating strong binders from weak binders,
and therefore, a positive correlation between the experimental
binding affinities and estimated binding affinities is desired. Our
two-step modeling strategy resulted in a high positive correlation
(R = 0.63) between the experimental and estimated affinities.
For each of the 12 peptidomimetics, we performed molecular
dynamics simulations for a production length of 10 ns. The
trajectory data for each simulation was output at 10 ps. Thus, we
obtained 1000 conformations for each peptidomimetic in complex
with the SH2 domain. The average fluctuation of the conforma-
tions of each peptidomimetic was measured as RMSF (root mean
square fluctuation) values. The weak binders displayed larger
fluctuation as compared to the strong binders. A clustering of the
conformations showed the preferred binding modes of the
peptidomimetics. Three strong binders, with IC50 values equal
to 190 nM (comp70), 83 nM (comp134), and 68 nM (comp121),
displayed three different but stable binding modes: the bent mode,
the extended mode, and the wedged mode respectively. The
peptidomimetics in these three binding modes showed very small
(,1.0 A˚) conformational fluctuations in the molecular dynamics
simulations, a large number of stable hydrogen bond interactions
Figure 7. Hydrogen bond occupancy. Hydrogen bond occupancy plots for each peptidomimetic are shown. In each sub-plot, the x-axis
represents the serial numbers of the residues of the SH2 domain of STAT3 and the y-axis represents the hydrogen bond occupancy value for a given
residue. Hydrogen bond occupancy is computed as the fraction of conformations out of 1000 conformations of a peptidomimetic in which the given
residue participates in a hydrogen bond. The 1000 conformations of each peptidomimetic were derived from the corresponding 10 ns molecular
dynamics trajectory. Note that a hydrogen bond is ignored if it is present in less than 500 conformations.
doi:10.1371/journal.pone.0051603.g007
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Figure 8. Correlation between experimental and esimated affinities. The top figure shows the variation of the Pearson correlation
coefficient (R), computed between the experimental binding affinities and the estimated binding affinities of the 12 peptidomimetics, with the length
of molecular dynamics simulation. The binding affinities were estimated using 4 different schemes. DGMMGBSA and DGMMPBSA represent non-
entropic contribution to the binding affinity computed using the MMGBSA and MMPBSA methods in AmberTools software package. TDS represents
the entropic contribution computed using the nmode method in AmberTools. The bottom figure shows, for each peptidomimetic, the estimated
binding affinity value computed using DGMMPBSA{TDS scheme. Because the values computed using MMGBSA, MMPBSA, and nmode methods are
averaged over the snapshots of the molecular dynamics trajectory, we also plot the variation of estimated binding affinity values with increasing
length of the molecular dynamics simulation.
doi:10.1371/journal.pone.0051603.g008
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Figure 9. Bent binding mode. The bent binding mode of peptidomimetic comp70 (in green) is shown. The peptidomimetic is in complex with the
SH2 domain of STAT3 which is shown in cartoon (top) and surface (bottom) representations. The residues of the SH2 domain which participate in
hydrogen bonds are labeled. The top figure also shows the hydrogen bonds (dashed lines) that the residues (in yellow) participate in. The surface
coloring shows the Coulombic electrostatic potential in the different regions of the surface of the SH2 domain. The potential ranges from positive (in
blue) to negative (in red). The IC50 value for comp70 is 190 nM.
doi:10.1371/journal.pone.0051603.g009
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Figure 10. Extended binding mode. The extended binding mode of peptidomimetic comp134 (in green) is shown. The peptidomimetic is in
complex with the SH2 domain of STAT3 which is shown in cartoon (top) and surface (bottom) representations. The residues of the SH2 domain which
participate in hydrogen bonds are labeled. The top figure also shows the hydrogen bonds (dashed lines) that the residues (in yellow) participate in.
The surface coloring shows the Coulombic electrostatic potential in the different regions of the surface of the SH2 domain. The potential ranges from
positive (in blue) to negative (in red). The IC50 value for comp134 is 83 nM.
doi:10.1371/journal.pone.0051603.g010
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with the residues of the SH2 domain, and the estimated binding
affinities value were low in accordance with the experimental
binding affinities.
Previous modeling studies related to SH2 domain binding have
proposed the bent and the extended binding modes [24,69]. In this
paper, we propose a new binding mode which we term the wedged
mode. In the wedged mode, the peptidomimetic (comp121) binds to
the SH2 domain such that the negatively charged phosphate group
of the pTyr residue sits inside a pocket which has a positive
electrostatic potential and the C-terminal benzyl group gets wedged
in a cavity formed by two loops of the SH2 domain described by the
residues 623–629 and 656–668 respectively. Apart from the stable
hydrogen bond interactions with the residues in the phosphate-
binding pocket, hydrogen bonds also exist between the peptidomi-
metic and residues on the two loops. The RMSF value for the 1000
conformations of the comp121 is 0.91 A˚ and is the lowest among
the RMSF values for the 12 peptidomimetics.
Despite the overall success of modeling strategy as described in
this paper, there were exceptions to the observed trends. For
example, in the case of comp140 which is a relatively strong binder
(IC50 = 105 nM), we obtained a large RMSF value and estimated
binding affinities that are comparable to those of weak binders.
This anomaly could be attributed to an inaccurate starting docked
conformation of the peptidomimetic. In the molecular dynamics
simulation, an inaccurate starting docked conformation would
result in trajectory that leads to inaccurate estimation of binding
affinity. It should be noted that computational docking of large
ligands such as peptidomimetics in our dataset is extremely
challenging. Although our incremental docking protocol improves
docking of large ligands, more work needs to be done in this area.
The computational modeling strategy described in this paper and
the subsequent data analysis, nonetheless, reveals important aspects
of the peptidomimetic binding to the SH2 domain of STAT3. Not
only were we able to estimate binding affinities that were well
correlated with experimental binding affinities, we were also able to
identify binding modes, including a novel wedge mode, that result in
stable binding interactions. A typical peptidomimetic drug design
process that is based on a specific motif involves designing
peptidomimetics with diverse chemical modifications. Accurate
estimation of binding affinities using our method could help in
predicting which modifications could lead to strong binding. The
knowledge gained by this study could also be used to improve the
design of the peptidomimetics by better targeting the sub-binding-
pockets identified in this paper with structural modifications or
conformational restraints. The proposed novel wedge binding mode
could prove very useful in this regard.
Supporting Information
Section S1 Incremental Docking Details.
(PDF)
Section S2 Modeling approach validation study.
(PDF)
Figure S1 MD simulation of comp1-SH2 complex. Total
energy (ETOT), potential energy (EPTOT), temperature (TEMP),
and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S2 MD simulation of comp13-SH2 complex. Total
energy (ETOT), potential energy (EPTOT), temperature (TEMP),
and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S3 MD simulation of comp15-SH2 complex. Total
energy (ETOT), potential energy (EPTOT), temperature (TEMP),
and pressure (PRES) over the course of 10 ns MD trajectory.
(PDF)
Figure S4 MD simulation of comp60-SH2 complex. Total
energy (ETOT), potential energy (EPTOT), temperature (TEMP),
and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S5 MD simulation of comp70-SH2 complex. Total
energy (ETOT), potential energy (EPTOT), temperature (TEMP),
and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S6 MD simulation of comp108-SH2 complex.
Total energy (ETOT), potential energy (EPTOT), temperature
(TEMP), and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S7 MD simulation of comp121-SH2 complex. Total
energy (ETOT), potential energy (EPTOT), temperature (TEMP),
and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S8 MD simulation of comp134-SH2 complex.
Total energy (ETOT), potential energy (EPTOT), temperature
(TEMP), and pressure (PRES) over the course of 10 ns MD
trajectory.
(PNG)
Figure S9 MD simulation of comp135-SH2 complex.
Total energy (ETOT), potential energy (EPTOT), temperature
(TEMP), and pressure (PRES) over the course of 10 ns MD
trajectory.
(PNG)
Figure S10 MD simulation of comp136-SH2 complex.
Total energy (ETOT), potential energy (EPTOT), temperature
(TEMP), and pressure (PRES) over the course of 10 ns MD
trajectory.
(PNG)
Figure S11 MD simulation of comp140-SH2 complex.
Total energy (ETOT), potential energy (EPTOT), temperature
(TEMP), and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S12 MD simulation of comp142-SH2 complex.
Total energy (ETOT), potential energy (EPTOT), temperature
(TEMP), and pressure (PRES) over the course of 10 ns MD trajectory.
(PNG)
Figure S13 Protein-ligand complex with PDB ID 1BM2.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure 11. Wedged binding mode. The proposed novel wedged binding mode of peptidomimetic comp121 (in green) is shown. The
peptidomimetic is in complex with the SH2 domain of STAT3 which is shown in cartoon (top) and surface (bottom) representations. The residues of
the SH2 domain which participate in hydrogen bonds are labeled. The top figure also shows the hydrogen bonds (dashed lines) that the residues (in
yellow) participate in. The surface coloring shows the Coulombic electrostatic potential in the different regions of the surface of the SH2 domain. The
potential ranges from positive (in blue) to negative (in red). The IC50 value for comp121 is 68 nM.
doi:10.1371/journal.pone.0051603.g011
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Figure S14 Protein-ligand complex with PDB ID 1CJ1.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S15 Protein-ligand complex with PDB ID 1IJR.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S16 Protein-ligand complex with PDB ID 1SKJ.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S17 Protein-ligand complex with PDB ID 1BKM.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S18 Protein-ligand complex with PDB ID 1IS0.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S19 Protein-ligand complex with PDB ID 1A08.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S20 Protein-ligand complex with PDB ID 1SHD.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S21 Protein-ligand complex with PDB ID 1SPS.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Figure S22 Protein-ligand complex with PDB ID 1ZFP.
The experimental conformation (green) and the modeled confor-
mation (yellow) of the ligand are shown in stick representation and
the protein is shown in surface representation.
(PNG)
Table S1 Number of atoms in MD simulation systems. MD
simulations were performed on 12 systems each comprising of one
of the 12 peptidomimetics in complex with the SH2 domain of
STAT3 in a explicit solvent box. This table lists the number of
atoms (Natoms) in each system.
(PNG)
Table S2 Validation accuracy. 10 protein-ligand complexes
were identified for validation of our modeling approach to predict
binding modes of peptidomimetics in complex with the SH2
domain of STAT3. This table lists the PDB IDs that correspond to
the deposited experimental structures of the 10 complexes. The
RMSD values between the modeled conformation and experi-
menal conformation of the ligands evaluate the accuracy of our
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